PP2A holoenzymes, substrate specificity driving cellular functions and deregulation in cancer
- PMID: 31349904
- PMCID: PMC9994639
- DOI: 10.1016/bs.acr.2019.03.009
PP2A holoenzymes, substrate specificity driving cellular functions and deregulation in cancer
Abstract
PP2A is a highly conserved eukaryotic serine/threonine protein phosphatase of the PPP family of phosphatases with fundamental cellular functions. In cells, PP2A targets specific subcellular locations and substrates by forming heterotrimeric holoenzymes, where a core dimer consisting of scaffold (A) and catalytic (C) subunits complexes with one of many B regulatory subunits. PP2A plays a key role in positively and negatively regulating a myriad of cellular processes, as it targets a very sizable fraction of the cellular substrates phosphorylated on Ser/Thr residues. This review focuses on insights made toward the understanding on how the subunit composition and structure of PP2A holoenzymes mediates substrate specificity, the role of substrate modulation in the signaling of cellular division, growth, and differentiation, and its deregulation in cancer.
Keywords: B55α; Cancer; Cell cycle; PP2A holoenzyme; PPP2R2A; Phosphorylation; Retinoblastoma protein (pRB); Serine/threonine protein phosphatases; Substrate specificity; p107.
© 2019 Elsevier Inc. All rights reserved.
Figures
References
-
- Abraham D, Podar K, Pacher M, Kubicek M, Welzel N, Hemmings BA, Dilworth SM, Mischak H, Kolch W, and Baccarini M (2000). Raf-1-associated protein phosphatase 2A as a positive regulator of kinase activation. J Biol Chem 275, 22300–22304. - PubMed
-
- Adams DG, Coffee RL, Zhang H, Pelech S, Strack S, and Wadzinski BE (2005). Positive regulation of Raf1-MEK1/2-ERK1/2 signaling by protein serine/threonine phosphatase 2A holoenzymes. J Biol Chem 280, 42644–42654. - PubMed
-
- Agarwal A, MacKenzie RJ, Pippa R, Eide CA, Oddo J, Tyner JW, Sears R, Vitek MP, Odero MD, Christensen DJ, and Druker BJ (2014). Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia. Clin Cancer Res 20, 2092–2103. - PMC - PubMed
-
- Agostinis P, Derua R, Sarno S, Goris J, and Merlevede W (1992). Specificity of the polycation-stimulated (type-2A) and ATP,Mg-dependent (type-1) protein phosphatases toward substrates phosphorylated by P34cdc2 kinase. Eur J Biochem 205, 241–248. - PubMed
-
- Akaike K, Suehara Y, Kohsaka S, Hayashi T, Tanabe Y, Kazuno S, Mukaihara K, Toda-Ishii M, Kurihara T, Kim Y, et al. (2018). regulated by PAX3/FOXO1 fusion contributes to the acquisition of aggressive behavior in PAX3/FOXO1-positive alveolar rhabdomyosarcoma. Oncotarget 9, 25206–25215. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
